Windtree Therapeutics Announces Issuance of New Dual Mechanism SERCA2a Activator Patent

Compounds that activate SERCA2a may lead to novel therapies for heart failure WARRINGTON, Pa. , April 17, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular